奥星药业 2025年度报告

Quarterly Report For the period endingDecember 31, 2025(the “Reporting Period”) Outstanding SharesThe number of shares outstanding of our Common Stock was: 381,209,195 as of December 31, 2025(Current Reporting Period Date or More Recent Date)381,209,195 as of June 30, 2025(Most Recent Completed Fiscal Year End) Shell StatusIndicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934): Yes:☐ Indicate by check mark whether the company’s shell status has changed since the previous reporting period: Yes:☐ Change in ControlIndicate by check mark whether a Change in Control4of the company has occurred during this reporting period: Yes:☐ (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act),directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding votingsecurities; (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the votingsecurities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of thesurviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent 1)Name and address(es) of the issuer and its predecessors (if any) In answering this item, provide the current name of the issuer and names used by predecessor entities, along with thedates of the name changes. The current name of the issuer is “Aoxing Pharmaceutical Company, Inc.”The issuer’s name was “China Aoxing Pharmaceutical Co., Inc.” until March 2010.The issuer's name was “Central American Equities Corp.” until July 2006. Current State and Date of Incorporation or Registration: FL, incorporated on 1/23/1996Standing in this jurisdiction: (e.g. active, default, inactive): Active Prior Incorporation Information for the issuer and any predecessors during the past five years: The issuer has been domiciled in FL since incorporation. In September 2019, the entity became inactive with the state ofFL for failure to file required annual reports. On August 11th2023, the Custodian reinstated the entity in FL and appointeda new Registered Agent. The entity remains in active status. Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessorssince inception: N/A List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated orthat occurred within the past 12 months: On September 12th2024, a collective group of buyers entered into a Securities Purchase Agreement for 305,000,000shares of Common Stock representing 80% control of the Company, which was closed subsequent to the period coveredby this report. On June 20, 2025, AOXG has acquired InfoEd Tech Limited, a Hong Kong-based EdTech innovator co-founded by Dr.Frankie Lo and Mr. Ramen Chim. Concurrently, AOXG will exit its legacy business in narcotics and neurologicalpharmaceuticals to focus exclusively on building an AI-powered, multilingual education platform for APAC. This dual move Address of the issuer’s principal executive office: Flat F, 9/F, Block 25, South Horizons,Apleichau, Hong Kong Address of the issuer’s principal place of business:☒Check if principal executive office and principal place of business are the same address: Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past fiveyears? No:☐Yes:☒If Yes, provide additional details below: On June 28th 2023, the Eleventh Judicial Circuit Court in Miami-Dade County, Florida, entered an Order appointing DavidDuarte as Custodian of Aoxing Pharmaceutical Company, Inc. (case number: 2022-021295-CA-01). Pursuant to theorder, the Custodian may take any actions which are reasonable, prudent, or for the benefit of the Company and it’sshareholders including but not limited to, reinstating the Company with the state of Florida, holding a shareholders On February 2nd 2024, the Eleventh Judicial Circuit Court granted the Custodian’s Motion to Discharge, and on February5th the Order Discharging Custodian and Termination of Custodianship was entered and control of the Company wasreturned to it’s Board of Direc